AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Zimmer Biomet Holdings, Inc. delivered a strong first quarter, with adjusted diluted earnings per share of $2.09 crushing Wall Street’s $1.86 estimate by 12.4%. The medical technology company’s results were based on estimates from 24 analysts tracking the stock.
The orthopedic device maker posted revenue of $2.09B for the quarter, narrowly surpassing the $2.07B forecast by 0.8%. That represented a robust 9.3% jump from the $1.91B recorded in the year-ago quarter, as demand for the company’s musculoskeletal healthcare products remained solid. Zimmer Biomet earned $409.4M in adjusted net income during the three-month period.
For the full fiscal year 2026, management projected adjusted EPS in the $8.40 to $8.55 range as the company continues executing its strategy in joint reconstruction, sports medicine, and dental implant markets. The guidance provides investors with a roadmap for the company’s performance expectations across its global operations.
Wall Street sentiment on the stock reflects a cautious stance, with consensus ratings standing at 8 buy, 20 hold, and 3 sell among analysts covering Zimmer Biomet. The mixed outlook suggests the Street is weighing the company’s growth trajectory against broader healthcare sector dynamics and competitive pressures in the medical device industry.
A detailed analysis of Zimmer Biomet Holdings, Inc.’s quarter follows shortly on AlphaStreet.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.